Siemens Healthineers has received CE-Mark for its new Atellica Solution with immunoassay and chemistry analysers, which will allow commercial launch in Europe.
The flexible, scalable, automation-ready in-vitro diagnostic (IVD) solution is designed to provide control and simplicity to diagnostic professionals, as well as mid and high-volume laboratories.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Atellica has the capability to combine up to ten components into more than 300 customisable configurations such as linear, L and U shapes.
The solution can be operated alone or with Aptio Automation and allows testing for clinical chemistry, immunoassay, haemostasis, haematology, and plasma protein analysers.
It also includes an immunoassay analyser that could run approximately 440 tests per hour.
Siemens Healthineers Laboratory Diagnostics president Franz Walt said: “The launch of the game-changing Atellica Solution revolutionises sample management and provides customers with unprecedented flexibility to future-proof their labs.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The Atellica Solution was developed through extensive market research with laboratory professionals around the world.”
The new IVD solution features a bidirectional, magnetic transport technology called Atellica Magline Transport, which is said to be ten times faster compared to standard sample conveyors.
In combination with a multi-camera vision system, intelligent sample routing, automatic quality control (QC) and calibration, the technology enables independent control over samples for quick results.
The solution could process more than 30 different types of sample containers such as paediatric and tube-top cups.
Atellica Solution comprises 170 assays, with ten minute turnaround times for primary cardiac, reproductive and thyroid tests, while there are an additional 50 assays in the pipeline.
The solution additionally includes dual incubation ring design, temperature and humidity controls, magnets for particle separation, remote-access monitoring, and self-recovery.
The solution is currently available in Europe, the US, South America, and Asia.
